In this study, we investigated whether HER3 expression could affect the therapeutic response to pertuzumab in HER2low pancreatic cancer by analyzing in vitro and in vivo pertuzumab effects in HER2low pancreatic cancer cell lines that express or not HER3. This evidence concerns the gene ERBB3 and familial pancreatic carcinoma.